Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

Inclusion Criteria:

• Aged 18 years old or more;

• Late stage NSCLC patients, with tumor invasion confirmed by histopathology analysis.Metastasis of axillary lymph nodes and other region lymph nodes are confirmed withhistopathologic or cytopathologic analysis;

• Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumor;

• No clinical evidence of other malignancy, unstable complication or uncontrolledinfection;

• Life expectancy > 12 months.

• Informed and signed consent by the patient.

Exclusion Criteria:

• Not accessible to biopsy and/or surgery sample;

• Patient already enrolled in another clinical trial with another first line ofchemotherapy;

• Unmeasurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria;

• Women who are pregnant, plan to become pregnant or are lactating during the study;

• Elevation of carcinoembryonic antigen (CEA) observed without distal metastases found;

• Have some kind of contraindications for chemotherapy and targeted therapy:cardiovascular and cerebrovascular diseases; liver and kidney function deficiency;hematological system diseases; clinician consider the patients are not suitable forchemotherapies or target therapies;

• Have other malignant tumor previously;

• Have surgical contraindications: anesthesia taboo; surgery unresectable extensivelesions;

• State of health can't finish the study;

• Patient already enrolled in another clinical trial with another anti-cancer therapy orplan to participate in other clinical study.

• No self-determination or refuse to participant.

• With unlisted exclusion criteria but are considered not suitable for the clinicalstudy by researchers.